2013
DOI: 10.1021/ol400399x
|View full text |Cite
|
Sign up to set email alerts
|

Efficient and Scalable Synthesis of Bardoxolone Methyl (CDDO-methyl Ester)

Abstract: Bardoxolone methyl (2-cyano-3,12-dioxooleane-1,9(11)-dien-28-oic acid methyl ester; CDDO-Me) (1), a synthetic oleanane triterpenoid with highly potent anti-inflammatory activity (levels below 1 nM), has completed a successful phase I clinical trial for the treatment of cancer and a successful phase II trial for the treatment of chronic kidney disease in type 2 diabetes patients. Our synthesis of bardoxolone methyl (1) proceeds in ∼50% overall yield in five steps from oleanolic acid (2), requires only one to tw… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
30
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 34 publications
(31 citation statements)
references
References 13 publications
(11 reference statements)
1
30
0
Order By: Relevance
“…Under name bardoxolone methyl (XX) it started, under auspices of Reata Pharmaceuticals (Dallas, TX, USA) parallel clinical trials, first to assess its anticancer properties and later towards advanced chronic kidney disease in patients with type 2 diabetis (Pergola et al, 2011). In parallel with Phase 1 clinical trials XX synthesis was elaborated into five-step scalable process, proceeding in about 50% overall yield from 105 (Fu & Gribble, 2013). Evident antioxidant and anti-inflammatory action, believed to operate via induction of transcription factor Nrf2, which reduces activity of the IKKβ/NFκB pathway suggested possibility of various other therapeutic indications.…”
Section: Semisynthetic Derivatives Of Oleanenementioning
confidence: 99%
See 1 more Smart Citation
“…Under name bardoxolone methyl (XX) it started, under auspices of Reata Pharmaceuticals (Dallas, TX, USA) parallel clinical trials, first to assess its anticancer properties and later towards advanced chronic kidney disease in patients with type 2 diabetis (Pergola et al, 2011). In parallel with Phase 1 clinical trials XX synthesis was elaborated into five-step scalable process, proceeding in about 50% overall yield from 105 (Fu & Gribble, 2013). Evident antioxidant and anti-inflammatory action, believed to operate via induction of transcription factor Nrf2, which reduces activity of the IKKβ/NFκB pathway suggested possibility of various other therapeutic indications.…”
Section: Semisynthetic Derivatives Of Oleanenementioning
confidence: 99%
“…C-28 imidazolide and analogs) of the active substance, which offers promise of new generation API. Process chemistry for semi-synthesis for CDDO analogs is clearly in sight (Fu & Gribble, 2013), which may be taken as an encouragement to start SAR supported exploratory chemistry with numerous polyhydroxyl analogs of 105.…”
Section: Semisynthetic Derivatives Of Oleanenementioning
confidence: 99%
“…One of the directions of their modification is the oxyfunctionalization of cycles А, C, and E, leading to new bioactive compounds [3][4][5][6][7][8][9][10][11][12][13][14].…”
mentioning
confidence: 99%
“…Methyl ester CDDO (methyl bardoxolone) passed the first phase of clinical trials as a drug for cancer treatment and second phase as a drug for treatment of chronical kidney diseases for patients suffering from sugar diabetes of the second type [5]. 12-Hydroxy-11-oxoolean-12-enes [3] exhibited a high cytotoxicity.…”
mentioning
confidence: 99%
“…Oxygenation of ring C is an important technique for modifying their structures in order to prepare new biologically active compounds. Examples include the synthesis from oleanolic acid of bardoxolone methyl (2-cyano-3,12-dioxooleane-1(2),9(11)-dien-28-oic acid methyl ester), which passed phase I clinical trials for treating cancer and phase II for treating chronic kidney disease in type 2 diabetes patients [4]. 3E,12D-Dihydroxyoleane-13E,28-lactone is a key intermediate in the synthesis of endothelin A receptor antagonists and a promising antidiabetic agent [5].…”
mentioning
confidence: 99%